cyclohexanol has been researched along with Brain Vascular Disorders in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Archer, DF; Cheng, RF; Guico-Pabia, CJ; Hwang, E; Pinkerton, JV | 1 |
| Cunningham, LA | 1 |
| Brilmyer, M; Kant, R; Zeiler, D; Zimmer, B | 1 |
| Dahmen, N; Hopf, HC; Marx, J; Röder, R; Tettenborn, B | 1 |
1 review(s) available for cyclohexanol and Brain Vascular Disorders
| Article | Year |
|---|---|
Depression in the medically ill: choosing an antidepressant.
Topics: Antidepressive Agents; Cerebrovascular Disorders; Clinical Trials as Topic; Comorbidity; Cyclohexanols; Decision Making; Dementia; Depressive Disorder; Humans; Neoplasms; Parkinson Disease; Prevalence; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 1994 |
2 trial(s) available for cyclohexanol and Brain Vascular Disorders
| Article | Year |
|---|---|
Cardiovascular, cerebrovascular, and hepatic safety of desvenlafaxine for 1 year in women with vasomotor symptoms associated with menopause.
Topics: Aged; Cardiovascular Diseases; Cerebrovascular Disorders; Chemical and Drug Induced Liver Injury; Cyclohexanols; Desvenlafaxine Succinate; Double-Blind Method; Female; Hot Flashes; Humans; Menopause; Middle Aged; Placebos; Risk Factors; Treatment Outcome | 2013 |
Therapy of early poststroke depression with venlafaxine: safety, tolerability, and efficacy as determined in an open, uncontrolled clinical trial.
Topics: Aged; Antidepressive Agents, Second-Generation; Cerebrovascular Disorders; Cyclohexanols; Depression; Female; Humans; Male; Venlafaxine Hydrochloride | 1999 |
1 other study(ies) available for cyclohexanol and Brain Vascular Disorders
| Article | Year |
|---|---|
Antidepressant efficacy and cardiovascular safety of venlafaxine in young vs old patients with comorbid medical disorders.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Blood Pressure; Cardiovascular Diseases; Cerebrovascular Disorders; Comorbidity; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Mood Disorders; Risk Factors; Venlafaxine Hydrochloride | 1997 |